NCT06254235View on ClinicalTrials.gov

Bioequivalence Study of Two Octreotide Microsphere Formulations in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

June 16, 2021

Primary Completion Date

December 1, 2021

Study Completion Date

December 1, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

The test octreotide microsphere

A single intramuscular dose of the test octreotide microsphere 30mg,

DRUG

The reference octreotide microsphere

A single intramuscular dose of the reference octreotide microsphere 30mg

Trial Locations (1)

266003

The Affiliated Hospital of Qingdao University, Qingdao

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY